BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

Communiqués Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Actions

2315

CNE100005D27

Recherche biotechnologique et médicale

Cours en clôture Hong Kong S.E. 06/10/2026			Varia. 5j.	Varia. 1 janv.
79,70 ^CNY	+11,47%		+23,18%	+125,78%

17/09	Biocytogen Pharmaceuticals ajuste son projet de levée de fonds et prolonge son calendrier	MT
02/09	Biocytogen Pharmaceuticals (Beijing) Co., Ltd. conclut un accord de licence non exclusif avec Qilu Pharmaceutical Co., Ltd. pour un anticorps VHH entièrement humain	CI

Communiqués

02/09	Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience	BU
02/09	Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience	BU
07/07	Biocytogen et Whitehawk Therapeutics concluent une collaboration mondiale pour le développement d’ADC à anticorps bispécifiques	BU
07/07	Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development	BU
07/07	Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development	BU
29/06	Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour	BU
29/06	Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour	BU
15/06	Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery	BU
15/06	Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery	BU
26/05	Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure	BU
26/05	Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure	BU
01/04	Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond	BU
01/04	Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond	BU
30/03	Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform	BU
30/03	Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform	BU
27/03	Biocytogen Announces FDA IND Clearance for Partner NEOK Bio's NEOK002 Targeting Solid Tumors	AQ
27/03	Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors	BU
27/03	Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors	BU
23/03	Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders	BU
23/03	Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders	BU
02/03	Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034	AQ
28/02	Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034	BU
28/02	Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034	BU
12/01	Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)	AQ
09/01	Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)	BU